カテゴリ： GlobalData, フランス, 企業調査

Poxel SA (POXEL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Poxel SA (POXEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C11500
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：69
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate carrier, and PXL770, an adenosine monophosphate-activated protein kinase, for non-alcoholic steatohepatitis (NASH) and metabolic diseases; and PXL007, for hepatitis B. Poxel is also developing earlier-stage programs, which includes deuterated drug candidates for the treatment of metabolic, specialty and rare diseases. It works in partnership with Sumitomo Dainippon Pharma, DeuteRx LLC and Roivant Sciences to research and develop products for metabolic disorders. The company is a spin-off from Merck Serono. Poxel is headquartered in Lyon, France.

Poxel SA (POXEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Poxel SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Poxel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Poxel SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Poxel SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Poxel Acquires DRX-065 from DeuteRx 11
Venture Financing 12
Poxel Raises Additional USD13 Million in Series B Venture Financing 12
Poxel Raises US$17 Million In Series B Financing 13
Partnerships 14
Enyo Pharma Enters into Agreement with Poxel 14
Poxel Enters into Agreement with INC Research 15
Licensing Agreements 16
Roivant Sciences Enters into Licensing Agreement with Poxel 16
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 17
ENYO Pharma Enters into Licensing Agreement with Poxel 18
Equity Offering 19
Poxel to Raise USD15 Million in Private Placement of Shares 19
Poxel Raises USD29.3 Million in Private Placement of Shares 20
Poxel Plans to Raise Funds through IPO 21
POXEL Raises USD21.9 Million in Private Placement of Shares 22
Poxel Raises USD29 Million in IPO 23
Acquisition 24
Merck Sante Sells 4.74% Stake in Poxel 24
Poxel SA – Key Competitors 25
Poxel SA – Key Employees 26
Poxel SA – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
Oct 16, 2018: Poxel reports third quarter and nine months 2018 financial update 28
Sep 19, 2018: Poxel announces financial results for the first half 2018 and provides corporate update 30
Jul 10, 2018: Poxel Announces Second Quarter and First Half 2018 Financial Update 33
Apr 23, 2018: Poxel Reports First Quarter 2018 Financial Results 34
Mar 22, 2018: Poxel Provides Business Update and Reports Results for Full Year 2017 35
Sep 21, 2017: Poxel Reports Results for the First Half 2017 and Provides Corporate Update 38
Jul 10, 2017: Poxel Announces Second Quarter 2017 Financial Update 41
May 04, 2017: Poxel Announces First Quarter 2017 Financial Update 42
Apr 03, 2017: Poxel Reports Results for Fiscal Year 2016 and Provides Corporate Update 43
Jan 27, 2017: Poxel Announces Fourth Quarter 2016 Financial Update 45
Corporate Communications 47
Jul 11, 2017: Poxel Appoints Kumi Sato to its Board of Directors 47
Apr 25, 2017: Poxel Announces Appointment of Anne Renevot as Chief Financial Officer 48
Mar 07, 2017: Poxel Announces Appointment of Christophe Arbet-Engels, MD, PhD, MBA, as Chief Medical Officer and EVP Late Development & Medical Affairs, Based in Boston 49
Product News 50
04/20/2017: Poxel to Present New Imeglimin Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan 50
03/21/2017: Poxel Announces Positive Results for Thorough QT Safety Clinical Study of Imeglimin 51
03/14/2018: DeuteRx to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference 52
Clinical Trials 53
Nov 12, 2018: Poxel presents promising data for PXL065 for the treatment of NASH at the American Association for the Study of Liver Diseases Meeting 53
Dec 27, 2017: Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan 55
Sep 20, 2017: Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial 57
Sep 14, 2017: Poxel Presents Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting 58
Sep 06, 2017: Poxel to Present Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting 60
Aug 28, 2017: Poxel Presents New Preclinical Imeglimin Data Demonstrating Improvement of Both Peripheral and Coronary Vascular Function at the European Society of Cardiology Congress 61
Jun 12, 2017: Poxel Presents New Preclinical Imeglimin Data on Improvement in Diastolic Function at the American Diabetes Association Meeting 62
Jun 06, 2017: Poxel Announces Additional Positive Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes 63
May 30, 2017: Poxel to Present New Preclinical Imeglimin Data on Protective Benefits from Diabetic Cardiomyopathy at the American Diabetes Association Meeting 64
May 22, 2017: Poxel Presents Imeglimin Japanese Phase 1 Results and Mechanistic Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan 65
May 04, 2017: Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes 66
Other Significant Developments 67
Jan 22, 2018: Poxel Announces Fourth Quarter 2017 Financial Update 67
Oct 16, 2017: Poxel Announces Third Quarter 2017 Financial Update 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Poxel SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Poxel SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Poxel SA, Deals By Therapy Area, 2012 to YTD 2018 9
Poxel SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Poxel Acquires DRX-065 from DeuteRx 11
Poxel Raises Additional USD13 Million in Series B Venture Financing 12
Poxel Raises US$17 Million In Series B Financing 13
Enyo Pharma Enters into Agreement with Poxel 14
Poxel Enters into Agreement with INC Research 15
Roivant Sciences Enters into Licensing Agreement with Poxel 16
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 17
ENYO Pharma Enters into Licensing Agreement with Poxel 18
Poxel to Raise USD15 Million in Private Placement of Shares 19
Poxel Raises USD29.3 Million in Private Placement of Shares 20
Poxel Plans to Raise Funds through IPO 21
POXEL Raises USD21.9 Million in Private Placement of Shares 22
Poxel Raises USD29 Million in IPO 23
Merck Sante Sells 4.74% Stake in Poxel 24
Poxel SA, Key Competitors 25
Poxel SA, Key Employees 26

List of Figures
Poxel SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Poxel SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Poxel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Poxel SA (POXEL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Arizona State University-製薬・医療分野：企業M&A・提携分析
    Summary Arizona State University (ASU) is an educational and research university that provides entrepreneurship solutions. The university’s services include academic services, knowledge enterprise development, institutes and initiative consulting, industry engagement, entrepreneurship, support and c …
  • Sabre Corporation (SABR)：企業の財務・戦略的SWOT分析
    Sabre Corporation (SABR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nuvelution Pharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Nuvelution Pharma Inc (Nuvelution Pharma) is a developer of late-stage clinical assets. The company offers research and development risk-sharing approach to pharmaceutical and biotechnology companies. It facilitates advancement of late-stage clinical assets where research and development bud …
  • Immucor, Inc.-医療機器分野：企業M&A・提携分析
    Summary Immucor, Inc. (Immucor) is an in-vitro diagnostics company, which specializes in the area of pre-transfusion diagnostics. It carries out the development, production and sale of a comprehensive line of reagents and automated systems. The company’s products are used in performing the tests to …
  • Golden Ocean Group Limited：企業のM&A・事業提携・投資動向
    Golden Ocean Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Golden Ocean Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Eversource Energy：発電所・企業SWOT分析
    Eversource Energy – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Mundipharma International Ltd：企業の戦略的SWOT分析
    Mundipharma International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Pan American Silver Corp：企業の戦略・SWOT・財務情報
    Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report Summary Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Trane Inc：企業の戦略的SWOT分析
    Trane Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Denison Mines Corp (DNN)：企業の財務・戦略的SWOT分析
    Denison Mines Corp (DNN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Exelon Generation Company LLC：発電所・企業SWOT分析
    Exelon Generation Company LLC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Mahagenco：企業の戦略的SWOT分析
    Mahagenco - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Silicon Laboratories Inc (SLAB)：企業の財務・戦略的SWOT分析
    Silicon Laboratories Inc (SLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Valio Ltd：企業の戦略的SWOT分析
    Valio Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Society for Worldwide Interbank Financial Telecommunication：企業の戦略的SWOT分析
    Society for Worldwide Interbank Financial Telecommunication - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, k …
  • ABB, Ltd.：企業の戦略・SWOT・財務情報
    ABB, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ABB, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Tomophase Corp：製品パイプライン分析
    Summary Tomophase Corp (Tomophase) is a medical device company that offers light-based imaging and therapy solutions. The company develops and commercializes opto-medical devices. It offers endoscopic tissue imaging system based on its proprietary technology optical coherence tomography. Tomophase's …
  • Mateon Therapeutics Inc (MATN)：企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • Strategic Resources Inc (STI)：企業の戦略的SWOT分析
    Strategic Resources Inc (STI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Noile-Immune Biotech Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Noile-Immune Biotech Inc (Noile-Immune Biotech) is a clinical stage biotechnology company that develops and commercializes next generation CAR-T cell therapies for the treatment of cancer. The company works in collaboration with National Cancer Center Japan and Yamaguchi University to develo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆